

Dear xxxx

## **Freedom of Information request: Treatment of Cancers (CORP 2024 – 148)**

Thank you for your request for information which the Trust received on 6<sup>th</sup> August 2024.

A copy of your request can be found below in Appendix 1.

Please find the Trust's response below:

The Trust does not record the data requested in a format that enables the information to be easily retrieved to the level of detail required to specifically answer your request. In reaching this decision we estimate that it would take a minimum of 26 hours, or £650 - an amount of £200 over the core amount of £450 extra to obtain the data. The amount would require payment in full prior to the Trust undertaking the work.

As result, the Trust is applying a Qualified Exemption under Section 12 (Exemption where cost of compliance exceeds appropriate limit), the legislation in this instance states:

### ***12 Exemption where cost of compliance exceeds appropriate limit.***

*(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.*


The Trust has a duty to advise and assist you under Section 16 of the Act and therefore may I suggest that you consider the option to revise your request so that it falls below the prescribed appropriate limit.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk)  
Head of Information Governance  
Velindre University NHS Trust  
2, Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff, CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.




Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales  
2nd Floor,  
Churchill House,  
Churchill Way,  
Cardiff,  
CF10 2HH  
Telephone: 0330 414 6421  
email: [wales@ico.org.uk](mailto:wales@ico.org.uk)

Yours sincerely

**Non Gwilym**  
**Interim Director of Corporate Governance**  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



## APPENDIX 1

### BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	
1.2 Alpelisib (Piqray)	
1.3 Fulvestrant (fulvestrant or Faslodex)	
1.4 Palbociclib (Ibrance)	
1.5 Ribociclib (Kisqali)	
1.6 Capivasertib (Truqap)	

Q2. How many patients received abemaciclib (Verzenios) for **early breast cancer** in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Number patients treated

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
3.1 Curative	
3.2 Palliative	
3.3 Not known / stated	

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre  
Velindre University NHS Trust Headquarters  
2 Cwrt Charnwood  
Heol Billingsley  
Parc Nantgarw  
Caerdydd/Cardiff  
CF15 7QZ  
Ffôn/Phone : (029) 20196161  
<https://velindre.nhs.wales>



Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of April 2024 and end of June 2024?

Type of breast cancer	Number patients treated
5.1 all types of breast cancer	
5.2 adjuvant treatment for early breast cancer	

### PROSTATE CANCER

Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Abiraterone (Zytiga or generic abiraterone)	
6.2 Apalutamide (Erleada)	
6.3 Cabazitaxel (Jevtana or generic cabazitaxel)	
6.4 Darolutamide (Nubeqa)	
6.5 Enzalutamide (Xtandi)	


Q7. How many patients were treated with these products specifically for **prostate cancer** (ICD-10 code = C61) in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
Docetaxel for prostate cancer	
Olaparib (Lynparza) for prostate cancer	

Q8. How many patients were treated with the following medicine combinations in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
8.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	
8.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	
8.3 Darolutamide (Nubeqa) + Docetaxel + ADT	
8.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	
8.5 Olaparib (Lynparza) + Abiraterone	

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.





Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre  
Velindre University NHS Trust Headquarters  
2 Cwrt Charnwood  
Heol Billingsley  
Parc Nantgarw  
Caerdydd/Cardiff  
CF15 7QZ  
Ffôn/Phone : (029) 20196161  
<https://velindre.nhs.wales>

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Q9. How many patients were treated with **abiraterone** for **non-metastatic hormone sensitive prostate cancer** in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
Abiraterone	

**OVARIAN and ENDOMETRIAL CANCERS**

Q10. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
10.1 Dostarlimab (Jemperli)	
10.2 Niraparib (Zejula)	
10.3 Rucaparib (Rubraca)	
10.4 Olaparib (Lynparza)	

Q11. How many patients were treated for **ovarian, fallopian tube or primary peritoneal cancers**, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
11.1 Olaparib in total	
11.2 Olaparib monotherapy	
11.3 Olaparib + bevacizumab in combination	
11.4 Bevacizumab total	
11.5 Bevacizumab monotherapy	
11.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

